- Dragan I, Georgiou T, Prodan N, Akolekar R, Nicolaides KH. Screening for pre-eclampsia using sFlt-1/PlGF ratio cut-off of 38 at 30-37 weeks' gestation. Ultrasound Obstet Gynecol 2017;49:73-77 pdf
- Panaitescu AM, Wright D, Militello A, Akolekar R, Nicolaides KH. Proposed clinical management of pregnancies after combined screening for preeclampsia at 35-37 weeks' gestation. Ultrasound Obstet Gynecol DOI: 10.1002/uog.17419 pdf
- Wright D, Dragan I, Syngelaki A, Akolekar R, Nicolaides KH. Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 30-34 weeks' gestation. Ultrasound Obstet Gynecol 2017;49:194-200 pdf
- Litwinska M, Wright D, Efeturk T, Ceccacci I, Nicolaides KH. Proposed clinical management of pregnancies after combined screening for preeclampsia at 19-24 weeks' gestation. Ultrasound Obstet Gynecol DOI: 10.1002/uog.17418 pdf
- Dragan I, Wright D, Fiolna M, Leipold G, Nicolaides KH. Development of preeclampsia within four weeks of sFLT to PLGF ratio >38: Comparison of performance at 31-34 versus 35-37 weeks' gestation. Ultrasound Obstet Gynecol 2017;49:209-12 pdf
- Tan MY, Wright D, Koutoulas L, Akolekar R, Nicolaides KH. Comparison of screening for preeclampsia at 31-34 weeks' gestation by the sFLT to PLGF ratio and a method combining maternal factors with sFLT-1 and PLGF. Ultrasound Obstet Gynecol DOI: 10.1002/uog.17307
- Tan MY, Wright D, Koutoulas L, Akolekar R, Nicolaides KH. Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF. Ultrasound Obstet Gynecol 2017;49:201-8 pdf
- Wright D, Krajewska K, Bogdanova A, Wright A, Nicolaides KH. Maternal serum soluble fms-like tyrosine kinase-1 at 22 and 32 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2016;47:755-61 pdf
- Tsiakkas A, Mendez O, Wright A, Wright D, Nicolaides KH. Maternal serum soluble fms-like tyrosine kinase-1 at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia. Ultrasound Obstet Gynecol 2016;47:478-83 pdf
- Khalil A, Maiz N, Garcia-Mandujano R, Penco JM, Nicolaides KH. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia. Ultrasound Obstet Gynecol 2016;47:324-31 pdf
- Wright D, Gallo DM, Gil Pugliese S, Casanova C, Nicolaides KH. Contingent screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol 2016;47:554-9 pdf
- Andrietti S, Silva M, Wright A, Wright D, Nicolaides KH. Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks' gestation. Ultrasound Obstet Gynecol 2016;48:72-9 pdf
- Tsiakkas A, Saiid Y, Wright A, Wright D, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation. Am J Obstet Gynecol 2016;215:87.e1-87.e17 pdf
- Gallo DM, Wright D, Casanova C, Campanero M, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation. Am J Obstet Gynecol 2016;214:619.e1-619.e17 pdf
- Valino N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH. Biophysical and biochemical markers at 35-37 weeks' gestation in the prediction of adverse perinatal outcome. Ultrasound Obstet Gynecol 2016;47:203-9 pdf
- Valino N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH. Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome. Ultrasound Obstet Gynecol 2016;47:194-202 pdf
- Birdir C, Fryze J, Vasiliadis H, Nicolaides KH, Poon LC. Maternal serum anti-Mallerian hormone at 11-13 weeks' gestation in the prediction of preeclampsia. J Matern Fetal Neonatal Med 2015;28:865-8 pdf
- Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides KH. Serum soluble fms-like tyrosine kinase-1 in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 2015;45:584-90 pdf
- Fadigas C, Peeva G, Mendez O, Poon LC, Nicolaides KH. Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks. Ultrasound Obstet Gynecol DOI: 10.1002/uog.14862 pdf
- Bakalis S, Peeva G, Gonzalez R, Poon LC, Nicolaides KH. Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 30-34 weeks. Ultrasound Obstet Gynecol DOI: 10.1002/uog.14863 pdf